ASONMEC

Asonmec is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics for autoimmune and inflammatory diseases. The company focuses on developing highly selective kinase inhibitors that aim to provide improved safety and efficacy profiles over existing treatments. Its lead candidate, ASM-101, is a potent Janus kinase 1 (JAK1) inhibitor currently in Phase 2 clinical trials for indications such as atopic dermatitis and alopecia areata. Asonmec is also advancing ASM-102, a selective Tyrosine kinase 2 (TYK2) inhibitor, through early-stage clinical development. The company leverages its expertise in medicinal chemistry to build a robust pipeline targeting significant unmet needs in dermatology and immunology.